Comparative Evaluation of the Efficacy of Topical Tacrolimus 0.03% and Topical Calcipotriol 0.005% Mixed With Betamethasone Dipropionate Versus Topical Clobetasol 0.05% in Treatment of Alopecia Areata: A Clinical and Trichoscopic Study

The study involved 60 patients with mild to moderate Alopecia Areata, divided into three groups of 20. Each group used a different treatment: topical tacrolimus 0.03%, a mix of topical calcipotriol 0.005% and betamethasone dipropionate, and topical clobetasol 0.05%. All treatments were applied twice daily for 3 months. The results showed significant decreases in positive pull test frequency and SALT scores post-treatment in all groups. Dermovate (clobetasol) had the highest hair regrowth rate (98%), followed by Daivobet (calcipotriol and betamethasone dipropionate) (89%), and tacrolimus (13%). However, at the 3-month follow-up, relapse was noted in 66% of patients treated with tacrolimus, 36.2% with Daivobet, and 25% with Dermovate. The study concluded that Daivobet was as effective as Dermovate, but with fewer side effects, making it more suitable for long-term use. Tacrolimus was not recommended due to its lower efficacy and higher relapse rate.